BioClinica has entered a partnership with Mirada Medical to integrate Mirada’s XD3 software solution into its imaging core lab technology for enhanced PET capabilities and molecular imaging trials. The software provides tools and efficient workflows for the quantification and tracking of findings for major modalities including PET, CT, MR and MR/PET.
 
The two companies have also entered a strategic partnership aimed at fostering innovation. BioClinica will integrate Mirada’s software platform into its processes and workflows, creating a design to advance BioClinica’s clinical capabilities and technologies such as BioPACS and BioREAD.

“Adding Mirada technology to our oncology trial process takes BioClinica’s already robust imaging core lab services to a new level,” said Dr. Andy Dzik-Jurasz, BioClinica’s senior medical director of Medical Affairs. “By adding XD3 to our workflow, BioClinica will offer the most sophisticated level of clinical analysis available for oncology PET scan image processing.”